Talkin’ Toxins: From Coley’s to Modern Cancer Immunotherapy
Abstract
The ability of the immune system to precisely target and eliminate aberrant or infected cells has long been studied in the field of infectious diseases. Attempts to define and exploit these potent immunological processes in the fight against cancer has been a longstanding effort dating back over 100 years to when Dr. William Coley purposefully infected cancer patients with a cocktail of heat-killed bacteria to stimulate anti-cancer immune processes. Although the field of cancer immunotherapy has been dotted with skepticism at times, the success of immune checkpoint inhibitors and recent FDA approvals of autologous cell therapies have pivoted immunotherapy to center stage as one of the most promising strategies to treat cancer. This review aims to summarize historic milestones throughout the field of cancer immunotherapy as well as highlight current and promising immunotherapies in development.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Apr 09, 2020
- Source ID
- 10.3390/toxins12040241
Entities
People
- Adam E. Snook
- John C. Flickinger Jr.
- Robert D Carlson
Organizations
- DeGregorio Family Foundation
- Pharmaceutical Research and Manufacturers of America
- United States Department of Defense